-
Chia Tai sky is open and hanging! 61 Class 1 new drugs and 7 blockbuster monoclonal antibody screens
Time of Update: 2022-10-19
Recently, the R&D pipeline of CP Tianqing Pharmaceutical welcomes new progress: class 1 new drug TQB2102 is declared for clinical for the first time, the introduction of heavy NASH new drugs, and cla
-
List of proprietary Chinese medicines that have passed the formal review of the national medical insurance catalogue in 2022
Time of Update: 2022-10-14
2022 Medical Insurance Catalogue Adjustment Review Catalogue of Chinese Proprietary Medicine The medical insurance directory access negotiations have been carried out four times since the establishment of the National Medical Insurance Bureau, and from the perspective of the 50 proprietary Chinese medicines that have passed the formal examination, the number of proprietary Chinese medicines outside the list has increased by 87.
-
Super hot target CD47/SIRPα
Time of Update: 2022-01-24
(“Borui Bio”) announced its self-developed humanized monoclonal antibody BR105 injection targeting SIRPα The clinical trial application for oncology treatment was approved by the National Medical Products Administration (NMPA) .
-
Two injections of Sansheng Guojian were approved for clinical use
Time of Update: 2021-10-22
On October 8, Sansheng Guojian issued an announcement stating that the company has recently received 4 "Drug Clinical Trial Approval Notices" approved and issued by the State Food and Drug Administrat
-
Clinical trial requirements for clinical drug registration management
Time of Update: 2021-09-19
Its purpose is to preliminarily evaluate the therapeutic effect and safety of the drug on patients with target indications, and also to provide a basis for the design of phase III clinical trials and the determination of the dosage regimen .
-
The State Food and Drug Administration announced the list of 15 batches of non-compliant drugs
Time of Update: 2021-08-02
were inspected by the Gansu Institute for Drug Control and were not in compliance with the regulations, and the non-compliant items were impurity; labeled as Hebei The 5 batches of Bupleurum (North Bupleurum) produced by Yuekang Zhide Pharmaceutical Co.
-
Pharmacy filing is not active
Time of Update: 2021-06-04
Therefore, it is very necessary for MAH (Holder of Drug Marketing Authorization) to hire a large number of medical representatives to conduct academic promotion to doctors and patients, and to analyze the product's characteristics, advantages, usage and dosage, indications, contraindications, precautions for use, and adverse reactions.
-
Procon Health Technology and Hutchison Medical reach clinical cooperation
Time of Update: 2021-03-27
Source: Guanlan PharmaceuticalOn February 23, Convalife announced that it has reached a clinical cooperation with Hutchison Pharmaceuticals to evaluate the high selection of PARP inhibitors Mefurpiride and Hutchison Pharmaceuticals with "best-in-class" potential for approval for listing The safety and tolerability of Fruquintinib combined with the treatment of solid tumors.
-
13 ministries issued a text to rectify the health care products market medical institutions must not do
Time of Update: 2021-02-05
13 ministries jointly carried out a 100-day operation to clean up the "health care" market chaos, medical institutions (clinics) must not make this mistake. 8, the State Administration of Market Sup
-
The next ride for the medical tycoon
Time of Update: 2020-10-24
, like Gan Li Pharmaceuticals, which has just landed in the capital markets this year, its chairman, Gan Zhongru, also announced shortly after the company's listing that he was retreating behind the scenes to do research and development, and arranged for "post-90" executives to step up to the stage.
-
Lilly VEGFR Inhibitor Portfolio approved Pfizer releases clinical results for oral JAK1 inhibitors
Time of Update: 2020-08-20
the trial showed a statistically significant reduction in the primary compound endpoint of major adverse cardiovascular events during the 36-month combination of aspirin and grillo compared to those with coronary heart disease and type 2 diabetes (T2D) who had a high risk of first heart attack or stroke.
-
Combined drug use can increase life expectancy and nearly double
Time of Update: 2020-08-07
If we can find ways to prolong healthy life expectancy and slow population ageing, we can offset the adverse effects of population ageing, which not only provides medical and economic benefits for countries, but also provides a better quality of life for their people." "Gruber team wanted to explore how long it can be extended to healthy life by combining drugs that target several possible biological pathways that affect life expectancy.
-
Hospital procurement of non-selected products, medical insurance fund will not pay
Time of Update: 2020-06-26
Guide: On June 15, Ningbo issued the Work Programme for the Central Quantity Of Medicines and Medical Supplies of Ningbo Public Medical Institutions, which openly solicited opinions from the community
-
Multi-measures of the health system in Qin City to build a harmonious doctor-patient relationship
Time of Update: 2020-05-12
Yan Zhao Metropolis Daily, Dong version of the reporter Yan Yunpeng intern Niu Liting in recent years, difficult to see a doctor, the tension between doctors and patients has become a mountain in
-
Guangdong Province: enterprises holding drug number directly become the holders of listing license
Time of Update: 2019-12-13
On December 12, Guangdong food and Drug Administration issued a circular on the implementation of the drug administration law of the people's Republic of China It is clear in the notice that, from Dec
